Navigation Links
Millennium Ranks in the Top 10 Best Biopharma Employers in the World by Science Magazine

CAMBRIDGE, Mass., Oct. 9 /PRNewswire/ -- Millennium: The Takeda Oncology Company today announced it has been named among the best biopharmaceutical companies in the world, according to Science magazine's annual survey of Top Employers in the biotechnology, biopharmaceutical, pharmaceutical and related industries. With a 2008 ranking of eighth, the Company is in the top ten for the first time, moving up from a 2007 ranking of 14.

(Logo: )

"This top ten ranking underscores Millennium's commitment not only to breakthrough science, but also to its employees and overall working environment," said Stephen Gansler, Senior Vice President, Human Resources, Millennium. "It is now more important than ever for us to keep up this positive work culture as we recruit for the hundreds of new additions over the next few months."

Respondents to the web-based survey were asked to rate companies based on 23 driving characteristics, including financial strength, easy adaptation to change and a research-driven environment. The 2008 survey sought to identify the companies with the best reputations as employers, based on nearly 4,000 survey responses from readers of Science and other respondents in industry. Twenty percent of the respondents came from outside the United States, primarily Western Europe, and 92 percent worked in private industry. For the complete business office feature with individual company rankings, please visit: es/ 2008_10_10/science.opms.r0800061.

Millennium was acquired by Takeda Pharmaceutical Company Limited in May, 2008.

About Millennium

Millennium Pharmaceuticals, Inc., a leading biopharmaceutical company based in Cambridge, Mass., markets VELCADE, a novel cancer product, and has a robust clinical development pipeline of product candidates. Millennium research, development and commercialization activities are focused in oncology. Additional information about Millennium is available through its website,

Editor's Note: This press release is also available under the Media section of the Company's website at:

Media Contact:

Manisha Pai


SOURCE Millennium Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Mark C. Mirken Named New CEO and Chairman of the Board of Millennium Biotechnologies, Inc.
2. Joseph B. Bolen, Ph.D. from Millennium to Conference Chair Cancer Sessions at IBCs Drug Discovery & Development of Innovative Therapeutics Conference
3. Millennium Biotechnologies Announces an Increased Annualized Purchase Commitment Totaling $5.8M from Provider Services, Inc.
4. Takeda Successfully Completes Tender Offer for Millennium Pharmaceuticals, Inc. and Announces Subsequent Offering Period
5. Takeda to Acquire Millennium for US$25.00 Per Share in an All Cash Tender Offer Valued at $8.8 Billion
6. Millennium Announces VELCADE(R) (Bortezomib) for Injection First-Quarter 2008 U.S. Net Sales
7. Millennium Announces $200,000 Purchase Order From Greek Distributor
8. Millennium Biotechnologies, Inc. Signs Marketing and Distribution Agreement with Ferring Pharmaceuticals
9. Millennium Over-Delivers on 2007 Goals and Financial Guidance
10. Millennium Biotechnologies Group Reports 40% Sales Increase for Resurgex Product Line in Greek Market
11. Millennium Announces 2008 Goals for Growth, Building on Record 2007 Results
Post Your Comments:
(Date:11/30/2015)... Germany , November 30, 2015 ... Vienna, Austria to be held December 1-4, ... in Vienna, Austria to be ... owned subsidiary of Vycor Medical, Inc. ("Vycor") (OTCQB: VYCO), announced ... Therapy Suite at the 3rd European Congress of NeuroRehabilitation ...
(Date:11/28/2015)... Korea (PRWEB) , ... November 28, 2015 , ... • ... of eco-friendly avian, porcine and rodent control solutions , ... peppermint and cinnamon oil, works across all sensory modalities including visual, smell, taste and ...
(Date:11/26/2015)... 26, 2015 ... Accutest Research Laboratories, a leading independent ... (CRO), has formed a strategic partnership ... Temple Health for joint work on ... ) , --> ...
(Date:11/25/2015)... , November 25, 2015 2 nouvelles ... fois les différences entre les souches bactériennes retrouvées ... des êtres humains . Ces recherches  ouvrent ... envisager la prise en charge efficace de l,un ... chez les chats .    --> 2 ...
Breaking Biology Technology:
(Date:11/9/2015)...  Synaptics Inc. (NASDAQ: SYNA ), the leading ... into the automotive market with a comprehensive and dedicated ... consumer electronics human interface innovation. Synaptics, industry-leading touch controllers, ... automotive industry and will be implemented in numerous locations ... , Japan , and ...
(Date:11/2/2015)... , Nov. 2, 2015  SRI International has ... to provide preclinical development services to the National Cancer ... SRI will provide scientific expertise, modern testing and support ... of preclinical pharmacology and toxicology studies to evaluate potential ... --> The PREVENT Cancer Drug Development Program is ...
(Date:10/29/2015)... , Oct. 29, 2015  The J. Craig ... report titled, "DNA Synthesis and Biosecurity: Lessons Learned and ... Department of Health and Human Services guidance for synthetic ... 2010. --> --> ... also has the potential to pose unique biosecurity threats. ...
Breaking Biology News(10 mins):